Volume 19, Issue 6 (November - December 2020)
Payesh 2020, 19(6): 735-747 |
Back to browse issues page
Ethics code: IR.SBMU.PHARMACY.REC.1398.307
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
esmaeili S, yousefi P, yousefi N. The Impact of the Production of Active Pharmaceutical Ingredients in Iran on Price, Quality, and access of Medicines. Payesh 2020; 19 (6) :735-747
URL: http://payeshjournal.ir/article-1-1215-en.html
URL: http://payeshjournal.ir/article-1-1215-en.html
1- School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Abstract: (2912 Views)
Objective (s): Active Pharmaceutical Ingredients (APIs) are a significant contributing factor to the price, quality, and access of pharmaceutical products. Thus countries often would develop their policy of supplying APIs based on these three factors. This study examined the impact of the supply policies of APIs on the price, quality, and access of medicines in Iran.
Methods: This study consisted of qualitative and quantitative phases. In the qualitative phase, semi-structured interviews were carried out with leading experts in the field, and thematic analysis method was used for data analysis. In the quantitative phase, the price of domestic APIs was compared to that from China and India in the case of 50 medicine products, and the ratio of the API price to the final product was determined. In addition, opinion of manufacturers of final products was asked about the quality of domestic and imported APIs.
Results: In 45 products, the price of domestic APIs was higher than that of their counterparts imported from China and India. Judging by the opinion of quality control experts in drug manufacturing companies, the quality of domestic APIs was also inferior to that of the imported ones.
Conclusion: Economic reasoning and quality of APIs in supply constitute the main business principles of final product manufacturers. To promote market of domestic active pharmaceutical ingredients, their price and quality should be improved.
Methods: This study consisted of qualitative and quantitative phases. In the qualitative phase, semi-structured interviews were carried out with leading experts in the field, and thematic analysis method was used for data analysis. In the quantitative phase, the price of domestic APIs was compared to that from China and India in the case of 50 medicine products, and the ratio of the API price to the final product was determined. In addition, opinion of manufacturers of final products was asked about the quality of domestic and imported APIs.
Results: In 45 products, the price of domestic APIs was higher than that of their counterparts imported from China and India. Judging by the opinion of quality control experts in drug manufacturing companies, the quality of domestic APIs was also inferior to that of the imported ones.
Conclusion: Economic reasoning and quality of APIs in supply constitute the main business principles of final product manufacturers. To promote market of domestic active pharmaceutical ingredients, their price and quality should be improved.
type of study: Descriptive |
Received: 2019/12/22 | Accepted: 2020/11/4 | ePublished ahead of print: 2020/12/1 | Published: 2020/12/20
Received: 2019/12/22 | Accepted: 2020/11/4 | ePublished ahead of print: 2020/12/1 | Published: 2020/12/20
References
1. Tahriri F, Osman M, Ali A, Yusuff R, Esfandyari A. AHP approach for supplier evaluation and selection in a steel manufacturing company. Journal of Industrial Engineering and Management (JIEM) 2008; 1: 54-76 [DOI:10.3926/jiem.2008.v1in2.p54-76]
2. Karris G. How will changes in India and China affect API outsourcing 2002. Available from: https://www.contractpharma.com/issues/2002-09/view_features/api-manufacturing November 2020
3. Kaplan W, Laing R. Local Production of Pharmaceuticals: Industrial Policy and Access to Medicines. 1st Edition, World Bank: Washington DC, USA, 2005
4. Active Pharmaceutical Ingredients (API). Available from: https://www.transparencymarketresearch.com/active-pharmaceutical-ingredients.html, 2017
5. World Health Organization. Local Production for Access to Medical Products: Developing a Framework to Improve Public Health 2011. Available from: https://www.who.int/phi/publications/local_production_policy_framework/en November 2020
6. Pharmaceutical production policy 2012. Available from: https://www.msh.org/sites/msh.org/files/mds3-ch07-production-policy-mar2012.pdf
7. Babar Z. Pharmaceutical Policy in Countries with Developing Healthcare Systems. 1st Edition, Springer International Publishing AG, Cham: Switzerland, 2017 [DOI:10.1007/978-3-319-51673-8]
8. Abbott FM. Comparative study of selected government policies for promoting transfer of technology and competitiveness in the colombian pharmaceutical sector 2007. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=1920926 November 2020
9. Abbott FM. Trends in local production of medicines and related technology transfer. World Health Organization 2011. Available from: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=1971924 November 2020
10. Bumpas J, Betsch E. Exploratory Study on Active Pharmaceutical Ingredient Manufacturing for Essential Medicines. 1st Edition, World Bank, Washington DC, USA, 2009
11. Abbott FM. TRIPS II, Asia and the Mercantile Pharmaceutical War: Implications for Innovation and Access 2006. Available from: https://siepr.stanford.edu/sites/default/files/publications/308wp.pdf November 2020
12. Chamas CI. Developing innovative capacity in Brazil to meet health needs 2005. Available from:
https://www.who.int/intellectualproperty/studies/MIHR-NOVATION%20EXPERIENCES%20OF%20South%20Africa,%20CHINA,%20BRAZIL%20AND%20INDIA%20MIHR-CiPIH%20REPORTS%2014-04-05.pdf?q=cipih#page=75 November 2020
13. Iran food and drug administration. supply of API in Iran 2019. Available from: https://www.yjc.ir/fa/news/6984435[Persian] November 2020
14. Amindoust A, Ahmed S, Ketabi S. Evaluation and selection of supplier in supply chain network based on DEA 2010. Available from: https://www.researchgate.net/profile/Atefeh_Amindoust/publication/216136894_Evaluation_and_Selection_of_Supplier_in_Supply_Chain_Network_Based_on_DEA/links/58b41b01aca2725b541b3e0b/Evaluation-and-Selection-of-Supplier-in-Supply-Chain-Network-Based-on-DEA.pdf November 2020
15. Austin Z, Sutton J. Qualitative research: Getting started. The Canadian Journal of Hospital Pharmacy 2014; 67: 436-440 [DOI:10.4212/cjhp.v67i6.1406]
16. Peek ME, Nunez-Smith M, Drum M, Lewis TT. Adapting the everyday discrimination scale to medical settings: reliability and validity testing in a sample of African American patients. Ethnicity & Disease 2011; 21: 502
17. Braun V, Clarke V. Using thematic analysis in psychology. Qualitative Research in Psychology 2006; 3: 77-101 [DOI:10.1191/1478088706qp063oa]
18. Attride-Stirling J. Thematic networks: an analytic tool for qualitative research. Qualitative Research in Psychology 2001; 1: 385-405 [DOI:10.1177/146879410100100307]
19. Drug Facts and Comparisons 2017. Available from: https://www.bookdepository.com/Drug-Facts-Comparisons-2017-Fact Comparisons/9781574393767 November 2020
20. World Health Organization. The World Medicines Situation 2004. Available from: https://apps.who.int/medicinedocs/pdf/s6160e/s6160e.pdf November 2020
Send email to the article author
| Rights and Permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |